|
KMID : 1142020230580000109
|
|
Blood Research
2023 Volume.58 No. 0 p.109 ~ p.113
|
|
|
Treatment after failure of frontline therapy of chronic myeloid leukemia in chronic phase including allogeneic hematopoietic stem cell transplantation
|
|
Uhm Ji-Eun
|
|
|
Abstract
|
|
|
|
The treatment outcomes of chronic myeloid leukemia in chronic phase (CML-CP) have dramatically improved with comparable life-expectancy to average of general population in tyrosine kinase inhibitor (TKI) era. However, less than a half of patients who started with TKI can remain on frontline TKI. The reasons of switching TKI can be either intolerance or the lack of efficacy. Although a kinase domain (KD) mutation can guide to select salvage TKI from the point of view on the efficacy of TKIs, many factors need to be considered before choosing next-line TKI such as the high-risk features of CML, the adverse events with prior TKI, and the comorbidities of patients. The therapeutic options for CML-CP after failing frontline TKI due to treatment failure or suboptimal responses will be reviewed including allogeneic hematopoietic stem cell transplantation.
|
|
|
KEYWORD
|
|
|
Chronic myeloid leukemia, Tyrosine kinase inhibitors, Ponatinib, Asciminib, Allogeneic hematopoietic stem cell transplantation
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|